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Summary
 
P-selectin glycoprotein ligand 1 (PSGL-1) is a mucin-like selectin counterreceptor that binds to
P-selectin, E-selectin, and L-selectin. To determine its physiological role in cell adhesion as a medi-
ator of leukocyte rolling and migration during inflammation, we prepared mice genetically defi-
cient in PSGL-1 by targeted disruption of the PSGL-1 gene. The homozygous PSGL-1–deficient
mouse was viable and fertile. The blood neutrophil count was modestly elevated. There was no
evidence of spontaneous development of skin ulcerations or infections. Leukocyte infiltration
in the chemical peritonitis model was significantly delayed. Leukocyte rolling in vivo, studied
by intravital microscopy in postcapillary venules of the cremaster muscle, was markedly de-
creased 30 min after trauma in the PSGL-1–deficient mouse. In contrast, leukocyte rolling 2 h
after tumor necrosis factor 
 
a 
 
stimulation was only modestly reduced, but blocking antibodies to
E-selectin infused into the PSGL-1–deficient mouse almost completely eliminated leukocyte
rolling. These results indicate that PSGL-1 is required for the early inflammatory responses but
not for E-selectin–mediated responses. These kinetics are consistent with a model in which
PSGL-1 is the predominant neutrophil P-selectin ligand but is not a required counterreceptor
for E-selectin under in vivo physiological conditions.
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ecruitment of leukocytes from the blood stream to
sites of injury or infection is initiated early in the in-
flammatory response. Cell–cell interactions among leuko-
cytes, platelets, and endothelial cells on the blood vessel
wall during this process are mediated by cell adhesion mol-
ecules that reside on the plasma membranes of these cells
(1). The initial contact and rolling of leukocytes on acti-
vated endothelium are mediated by the selectins (2, 3).
Chemoattractants, together with signals generated by cell–
cell interaction, activate integrins on leukocytes, leading to
firm attachment and migration of leukocytes into tissues.
The selectin family of adhesion molecules includes E-selec-
tin, L-selectin, and P-selectin. P-selectin, stored in the
alpha granules in unstimulated platelets and the Weibel-
Palade bodies in resting endothelial cells, is translocated to
the cell surface upon cell activation (4, 5). In mice lacking
P-selectin, neutrophil rolling in venules of the mesentery
or the cremaster muscle is nearly absent at early time points
and neutrophil influx into the inflamed peritoneum is de-
layed (6–8). Cell surface expression of E-selectin is induced
at the transcriptional level after endothelial stimulation by
cytokines (9), so E-selectin expression is a late event after
de novo synthesis. E-selectin–deficient mice do not show
obvious defects in leukocyte function, although slow roll-
ing is impaired (10). L-selectin is expressed constitutively
on leukocytes. Significant inhibition in neutrophil rolling
at later time points is observed in L-selectin–deficient mice
(7, 11). Mice deficient in both P-selectin and E-selectin
demonstrate minimal neutrophil rolling and delayed and
suppressed neutrophil migration (12, 13).
The physiologically relevant counterreceptors on cell sur-
faces that bind specifically to selectins have been difficult to
identify, although many putative selectin ligands have been
proposed. The selectins are lectins, and the selectin ligands
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include Lewis X (CD15 [14]) and sialic acid (15, 16). Oli-
gosaccharide sequences of the ligands, predominantly sialyl
Lewis X antigen–related sialylated fucosylated lactosamine,
are recognized by these selectins but with low affinity. To
date, several mucin-like proteins have been reported to bind
to L-selectin, P-selectin, and E-selectin. Putative L-selectin
ligands include E-selectin and P-selectin (17), glycosylation-
dependent cell adhesion molecule 1 (GlyCAM-1 [18]), CD34
(19, 20), sialoglycoprotein 200 (Sgp 200 [21]), mucosal ad-
dressin cell adhesion molecule 1 (MAdCAM-1 [22]), and
P-selectin glycoprotein ligand 1 (PSGL-1)
 
1
 
 (23–30). Putative
ligands for E-selectin include E-selectin ligand 1 (ESL-1 [31]),
L-selectin (32, 33), and PSGL-1 (34–40). Mouse E-selectin
also binds PSGL-1 (33; and Hirata, T., B.C. Furie, and B.
Furie, unpublished results). Although in vitro studies have
indicated binding under certain conditions, none of these
ligands has been shown in animal models to mediate physio-
logically relevant interactions with L-selectin or E-selectin.
The putative P-selectin ligands include CD24 (41–43),
sulfated glycolipids (44), components of the peripheral node
addressin (PNAd) complex (45), and PSGL-1 (34, 46). Of
these, only PSGL-1 has been implicated as a biologically
important ligand for P-selectin (34; for a review, see Varki
[47]). The functional importance of PSGL-1 as a P-selectin
ligand was suggested from studies in which blocking antibod-
ies to PSGL-1 inhibited P-selectin–mediated leukocyte roll-
ing in exteriorized rat mesentery venules (48) and prevented
the early P-selectin–directed accumulation of neutrophils in a
mouse model of peritoneal inflammation (49). Furthermore,
infusion of soluble PSGL-1 prevents acute inflammation in
transient ischemia in a rat kidney model (50).
PSGL-1 is expressed as a functional ligand of P-selectin
on myeloid cells and T lymphocyte subsets (40, 51–54).
PSGL-1 was identified by expression cloning from COS cells
that were cotransfected with a human HL-60 cDNA li-
brary and an 
 
a
 
1,3/1,4-fucosyltransferase (34). The mouse
homologue of PSGL-1 was subsequently cloned based on
sequence similarity (55). The predicted protein sequence
reveals a type I integral membrane protein of 402 residues
for human PSGL-1 and 397 residues for mouse PSGL-1.
The mature PSGL-1 protein begins at residue 42 after pro-
teolysis of a signal peptide and cleavage of a propeptide by a
furin-like converting enzyme (52). Human PSGL-1 is a
homodimer of 
 
z
 
210,000 molecular weight, with the two
chains covalently linked by a disulfide bond. Formation of
the homodimer is required for high-affinity binding of
PSGL-1 to P-selectin (56, 57). The P-selectin binding do-
main of PSGL-1 is located within the first 20 residues of
the mature PSGL-1 (58, 59). The NH
 
2
 
-terminal binding
domain of human PSGL-1 includes tyrosine sulfate and is
also 
 
O
 
-glycosylated (58–60). PSGL-1 contains a serine/
threonine- and proline-rich decameric repeat region. Mouse
PSGL-1 contains 10 repeat units (55). Human PSGL-1 from
 
eosinophils (61), HL-60, and U937 cells contains 15 repeat
units; PSGL-1 from human polymorphonuclear leukocytes
and monocytes contains 16 repeat units (62). PSGL-1 con-
tains O-linked glycans that form highly extended structures
that participate with the NH
 
2
 
-terminal binding domain of
PSGL-1 to bind the counterreceptor (63, 64).
To clarify the physiological role of PSGL-1, we gener-
ated mice deficient in PSGL-1. Using this mouse model,
we explored the consequences of the absence of PSGL-1 in
vivo to leukocyte rolling and leukocyte migration. We dem-
onstrate that PSGL-1 deficiency impairs early neutrophil
migration and trauma-induced leukocyte rolling. Our re-
sults indicate that in vivo PSGL-1 is required for the earliest
steps in the inflammatory response but is not required for cy-
tokine-induced, E-selectin–mediated leukocyte rolling.
 
Materials and Methods
 
Cell Lines and Tissue Culture.
 
The embryonic stem (ES) cell
line WW6 (65) was generated by F. Poirier and E.J. Robertson
(Harvard University) from a mouse (50% 129Sv, 25% C57BL/6,
5% SJL, and 20% unknown) and provided by Dr. P. Stanley (Al-
bert Einstein College of Medicine, New York, NY). Cells were
cultured on 
 
g
 
-irradiated STO feeder cells (SNL2; developed by
E.J. Robertson) in DMEM (GIBCO BRL) containing 20% FCS
(Hyclone).
 
Construction of the Targeting Vector.
 
Genomic clones of mouse
PSGL-1 were isolated from an adult 129/SvJ mouse liver geno-
mic DNA library (no. 946305; Stratagene) as described previ-
ously (55). Two contiguous EcoRI fragments together contain-
ing a portion of the 5
 
9
 
 flanking region, the complete coding region,
and the complete 3
 
9
 
 untranslated region of the PSGL-1 gene
were cloned independently into the pBluescript vector to create
A1.6 and A1.1 (see Fig. 1 A). An SmaI-EcoRI fragment from
A1.6 and an EcoRI-BamHI fragment from A1.1 were recom-
bined in pBluescript at the EcoRV and BamHI sites to generate
A
 
SMB
 
. A HindIII (blunt ended)-BamHI fragment released from
A
 
SMB
 
 was ligated 3
 
9
 
 to the Neo cassette in pNT at Xbal (blunt
ended) and BamHI sites to create KOIII. The vector pNT was
provided by Dr. B. Spiegleman (Dana-Farber Cancer Institute, Bos-
ton, MA). Primer pairs P1/P2 and P3/P4 were used to amplify the
DNA sequence by PCR to be inserted 5
 
9
 
 to the Neo cassette.
The PCR product from NotI-tagged P1 (5
 
9
 
-CCCCA ACGGG
TTGTT TTGGC CCACC-3
 
9
 
) and EcoRI-tagged P2 (5
 
9
 
-GAAGC
CGGAA GGGTC TGGGC ATGG-3
 
9
 
) was subcloned and re-
combined at the EcoRI site with the PCR product from EcoRI-
tagged P3 (5
 
9
 
-AGAATC TCATT GAGTT ACACA GCC-3
 
9
 
)
and XhoI-tagged P4 (5
 
9
 
-GGGGT CCTGC AGCTG AAGGC
TG-3
 
9
 
). The resulting 1.3-kb fragment was inserted at the NotI
and XhoI sites of KOIII to create KO.pNT.
 
Selection of Homologous Recombinants.
 
WW6 cells (2 
 
3 
 
10
 
7
 
)
were electroporated (GenePulser, 500 
 
m
 
F, 240 V; Bio-Rad) with
the targeting vector DNA (
 
z
 
30 
 
m
 
g/ml) that was linearized by
NotI digestion. Cells were plated onto monolayers of 
 
g
 
-irradi-
ated feeder cells. After 24 h, medium was replaced with medium
containing 200 
 
m
 
g/ml of G418 (GIBCO BRL) and 2 
 
m
 
M ganci-
clovir (Syntex). Individual colonies were picked 7 d after applica-
tion of selective media.
 
Screening of Recombinants and Generation of Homozygous Null
Mice.
 
Genomic DNA from individual colonies was isolated, di-
gested with HindIII, and analyzed by Southern blotting using
 
1
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probes B or C and Neo. One positive clone, W19, was ex-
panded. ES cells from clone W19 were injected into C57BL/6
blastocysts. The blastocysts were transferred to pseudopregnant
foster mothers. Four chimeric male mice were obtained and bred
with C57BL/6 mice. Germline transmission was identified by
Southern analysis of EcoRI-digested DNA using probe A. Hetero-
zygous animals were bred to generate mutant mice. All studies
and procedures were approved by the Animal Care and Use
Committee of Beth Israel Deaconess Medical Center.
 
Northern Blot Analysis.
 
Total RNA samples (20–60 
 
m
 
g) were
prepared from spleen and thymus obtained from PSGL-1
 
2
 
/
 
2
 
 and
PSGL-1
 
1
 
/
 
1
 
 mice using the SV Total RNA Isolation System
(Promega). RNA samples were separated by electrophoresis in 0.8%
agarose-formaldehyde gels using 1
 
3
 
 3-(
 
N
 
-morpholino)propane-
sulfonic acid (Mops) buffer (40 mM Mops, 10 mM sodium ace-
tate, and 1 mM EDTA, pH 7.0). The RNA was transferred to
a Duralon-UV™ membrane (Stratagene) and affixed to the
membrane by incubation at 80
 
8
 
C for 1 h. Prehybridization or hy-
bridization was at 65
 
8
 
C overnight in 50 mM piperazine-
 
N
 
,
 
N
 
9
 
-
bis(2-ethanesulfonic acid) (Pipes), pH 6.5, 100 mM sodium chlo-
ride, 50 mM sodium phosphate, pH 7.0, 1 mM EDTA, 5% SDS,
and 60 
 
m
 
g/ml salmon sperm DNA. The probe was a 1.0-kb PCR
fragment amplified from the coding region of mouse PSGL-1
(probe D).
 
Flow Cytometry Analysis.
 
Mice were bled from the retroor-
bital sinus into EDTA-anticoagulated tubes while under anesthe-
sia with Metofane (Mallinckrodt Veterinary). Leukocytes were
prepared by red cell lysis followed by washing and centrifugation.
Cells were incubated for 10 min with Fc Block (anti-CD32/16;
PharMingen) before all staining procedures. Cells were incubated
on ice for 30 min with 10 
 
m
 
g/ml of affinity-purified anti–PSGL-1
antibody or rabbit nonimmune IgG in PBS containing 1% FCS
and 0.04% azide, washed, and stained with FITC-labeled goat
anti–rabbit IgG (Sigma Chemical Co.) and PE-conjugated anti-
Ly6G (PharMingen). Analysis was performed on a FACSCalibur™
flow cytometer with CELLQuest™ software (both from Becton
Dickinson). Light-scatter gating procedures were used to enrich
for granulocytes.
 
Immunohistochemistry.
 
Fresh frozen sections were fixed with
80% acetone, and samples were treated with normal goat serum
for 1 h at 25
 
8
 
C. The sections were then incubated with rabbit
anti–mouse PSGL-1 antibody at 0.5 
 
m
 
g/ml in PBS for 16 h at
4
 
8
 
C. The tissue was washed three times for 5 min with PBS at
23
 
8
 
C. The washed sections were incubated with biotinylated goat
anti–rabbit antibody (VectaStain™ Elite ABC staining kit, 1:200
dilution; Vector Labs) for 1 h at 23
 
8
 
C. Sections were washed
three times and then incubated with peroxidase-conjugated
streptavidin for 1 h at 25
 
8
 
C. After three washes, the tissue sec-
tions were stained using 3,3
 
9
 
-diaminobenzidine in 40 mM Tris
buffer, pH 7.4, and then counterstained with methylene blue.
 
Anti–mouse PSGL-1 Antibodies.
 
A polyclonal antibody di-
rected against PSGL-1 was prepared using a synthetic peptide
(QVVGDDDFEDPDYTYC) based on residues 42–56 of mouse
PSGL-1 as immunogen (55). A cysteine residue was added at the
COOH terminus to facilitate coupling to KLH. The peptide was
synthesized using FMOC/
 
N
 
-methylpyrolidone chemistry on a
peptide synthesizer (model 430A; Applied Biosystems). After
cleavage and deprotection, the peptide was purified to homoge-
neity by reverse phase HPLC using a C18 column. The peptide
was covalently coupled to KLH through the free cysteine, and
the conjugate was injected intradermally (550 
 
m
 
g/ml) in com-
plete Freund’s adjuvant into a New Zealand White rabbit. Subse-
quent injections of immunogen (250 
 
m
 
g) were performed weekly
for 2 wk, then monthly thereafter. Antipeptide antibodies were
purified from rabbit immune serum by immunoaffinity chroma-
tography. The serum was applied to a KLH-Sepharose column to
remove antibodies against KLH. The serum proteins that failed to
bind to KLH-Sepharose were then applied to a PSGL-1 (residues
42–56)–Sepharose column in which the peptide was covalently
attached to Sulfo-Link Resin (Pierce Chemical Co.). Bound anti-
bodies were eluted with 4 M guanidine and dialyzed into PBS.
 
Peripheral Blood Counts.
 
Blood was collected from 8–10-wk-
old male wild-type and PSGL-1
 
2
 
/
 
2
 
 mice as well as P-selectin
 
2
 
/
 
2
 
mice and their matched controls. Complete blood counts were
performed using a Coulter Counter. Differential counts were
performed on blood smears stained with Wright-Giemsa stain
(Sigma Chemical Co.). Differentials were performed in duplicate
on 100 leukocytes per slide.
 
Thioglycollate-induced Peritonitis Model.
 
PSGL-1
 
2
 
/
 
2
 
 mice and
wild-type mice of similar mixed genetic background were used at
8–12 wk of age. P-selectin
 
2
 
/
 
2
 
 mice (C57BL/6 background) and
wild-type C57BL/6 mice (The Jackson Laboratory) were of the
same age. Mice were injected intraperitoneally with 1 ml of 4%
Brewer thioglycollate medium (Difco). At each time point after
stimulation, the mice were killed and 10 ml of PBS containing
1% bovine serum albumin, 0.5 mM EDTA, and 10 U/ml hep-
arin was injected into the peritoneal cavity. After gently massag-
ing the peritoneal wall, the injected wash was withdrawn. Total
cell numbers in the peritoneal lavage were determined on a
Coulter Counter. Cytospin preparations of the cells were stained
with Wright-Giemsa stain, and a differential leukocyte count was
determined. From the total cell count in the peritoneal lavage
and the percentage of neutrophils on cytospin preparations, the
absolute number of neutrophils was calculated.
 
Leukocyte Rolling In Vivo in the Mouse Cremaster Muscle.
 
Mice
were preanesthetized with an intraperitoneal injection of 125
mg/kg of ketamine HCl (Parke Davis), 12.5 mg/kg xylazine
(Phoenix Pharmaceuticals), and 0.25 mg/kg atropine sulfate
(American Reagent Laboratories). A trachea tube was inserted to
facilitate spontaneous respiration, and the mice were kept on a
37
 
8
 
C thermocontrolled rodent blanket (Thermal Care) during
the experiment. To maintain anesthesia and neutral fluid balance,
Nembutal (5 mg/ml in saline) was administered in 30–50 
 
m
 
l bo-
luses through a cannula placed in the jugular vein. Mean arterial
blood pressure ranged between 60 and 100 mmHg as measured
on a physiological pressure transducer (model 60-051; Harvard
Apparatus) connected to a carotid artery cannula. When TNF-
 
a
 
was used, mice were treated with an intrascrotal injection of
mouse TNF (0.5 
 
m
 
g in 200 
 
m
 
l saline; R&D Systems) 2 h before
exteriorization of the cremaster muscle. In experiments where
the neutralizing anti–E-selectin mAb 9A9 was used, mice were
injected with 80–90 
 
m
 
g of antibody through the jugular cannula
just after exteriorization of the cremaster muscle.
The cremaster muscle was prepared for intravital microscopy as
described by Ley et al. (7). Through an incision made in the scro-
tum, the testicle and surrounding cremaster muscle were exterior-
ized onto an intravital microscopy tray. After removal of the con-
nective tissue, a longitudinal incision was made in the cremaster,
and the muscle was carefully stretched and pinned across the intra-
vital microscopy stage while the testis and epididymis were tacked
to one side. The cremaster preparation was superfused with ther-
mocontrolled (36
 
8
 
C) and aerated (5% CO
 
2
 
, 95% N
 
2
 
) bicarbonate
buffered saline throughout the experiment. The cremaster exteri-
orization surgery was typically accomplished in 4–7 min.
Microvessel data were obtained using an intravital microscope
(Axioskop; Carl Zeiss, Inc.) fitted with an Achroplan (40
 
3
 
, 0.80 
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numerical aperture) water immersion objective, long distance
condenser, and stabilized D.C. power supply. Leukocyte rolling
in the venules was recorded for 75–90 s using a Sony CCD cam-
era (model SSC-S20) connected through an IBM-compatible
computer to a Sony SVHS video recorder (model SVA-9500MD).
The centerline red blood cell velocity (
 
V
 
cl
 
) in each venule was
measured in real time with a dual photodiode velocimeter run-
ning a digital cross-correlation program on an IBM-compatible
computer (Microvessel Velocity OD-RT; CircuSoft Instrumen-
tation). A Coulter Counter (model T890) was used to determine
the systemic leukocyte counts from 30–50 
 
m
 
l blood samples
taken from the carotid cannula at 30–40-min intervals or after in-
jection of antibodies. After the start of the cremaster surgery, data
were acquired for 30 or 40 min in the untreated and TNF-
treated mice, respectively.
 
Analysis of Leukocyte Rolling.
 
Video recordings from the in-
travital microscopy experiments were analyzed on a computer-
based image acquisition system, and vessel diameter was deter-
mined using the IBM-adapted version of NIH Image (Scion
Corp.). The centerline red cell velocity recorded from each vessel
was used to determine the volumetric blood flow (
 
Q
 
) via the
equation 
 
Q
 
 
 
5 
 
(
 
V
 
cl
 
)(0.625)(
 
A
 
cs
 
), where 
 
A
 
cs
 
 is the cross-sectional
area of the cylindrical vessel, and 0.625 is an empirical correction
factor (66). For each vessel, wall shear rate (
 
W
 
sr
 
) was determined:
 
W
 
sr
 
 
 
5 
 
2.13 
 
3 
 
[(8 
 
3
 
 0.625 
 
3
 
 
 
V
 
cl
 
)/
 
D
 
v
 
)], where 
 
D
 
v
 
 is the vessel di-
ameter. Critical velocity (
 
V
 
crit
 
) was also calculated: 
 
V
 
crit
 
 
 
5 
 
(
 
V
 
cl
 
 
 
3
 
0.625)(
 
D
 
cell
 
/
 
D
 
v
 
)[(2 
 
2 
 
(
 
Dcell/Dv)]. Recordings of each vessel were
analyzed for 30–60 s, and rolling leukocytes were identified as the
visible cells passing through a plane perpendicular to the vessel axis.
In certain cases, the rolling velocity of visible high velocity cells
(Vcell) was estimated in order to determine whether these cells
qualified as rolling leukocytes, defined Vcell , Vcrit. Total leukocyte
flux was determined as the product of the measured systemic leu-
kocyte concentration and microvessel volumetric blood flow. To
compensate for differences in systemic leukocyte count, the rolling
behavior of leukocytes in the cremaster muscle is presented as the
rolling leukocyte flux fraction, which is the number of rolling leu-
kocytes in the vessel as a percentage of the total leukocyte flux.
Online Supplemental Materials. We have included six video-
clips from representative experiments depicted in Figs. 6 and 7.
These experiments correspond directly to those used to prepare
the still photos in Figs. 6 and 7. Leukocyte rolling in the venules
was recorded for 75–90 s using a CCD camera connected
through an IBM-compatible computer to an SVHS video recorder.
Fig. 7 C was videotaped at an accelerated rate to compress the
images into a shorter time span.
Figure 1. Disruption of the
PSGL-1 gene in mice: targeting
vector and Southern blot analy-
sis. (A) Partial restriction maps of
the PSGL-1 gene and the target-
ing vector KO.pNT. Restriction
enzyme sites are marked as fol-
lows: E, EcoRI; H, HindIII; B,
BamHI; S, SmaI; N, NotI.
Probes used for Southern analy-
ses (A–D, Neo), primers used for
generating the vector (P1–P4),
and the repeat elements are indi-
cated. (B) Southern blot analyses
of ES clones. Genomic DNA
from two clones, W19 and W34,
were digested with HindIII. Af-
ter gel electrophoresis, DNA was
transferred to the membrane and
hybridized with probe C. The
blot was stripped and reprobed
with probe Neo. The targeted
band (KO) and the wild-type
band (WT) are indicated. (C)
Southern blot analyses of DNA
isolated from F1 and F2 genera-
tions. Genomic DNA from tail
biopsies was digested with
EcoRI. The fragments were sep-
arated by gel electrophoresis,
transferred to a membrane, and
hybridized with probe A. The
bands corresponding to the tar-
geted allele (KO) and the wild-
type allele (WT) are indicated.1773 Yang et al.
Results
Generation of PSGL-1–deficient Mice. Several ubiquitous
transposon-like repetitive sequences B1 and B2 (67) were
found in the 59 and 39 flanking regions of the PSGL-1 cod-
ing region, and two segments containing CT repeats similar
to those in ribosomal DNA (68) were located 59 to the
PSGL-1 coding region (Fig. 1 A). These repetitive sequences
were excluded from the knockout vector, KO.pNT, in
which a small region of the PSGL-1 coding sequence from
69 to 94 nucleotides (nt) was replaced by a neomycin-resis-
tance gene cassette (Fig. 1 A). A deletion of z300 bp in the
59 flanking region of the PSGL-1 coding region was gener-
ated in the vector in order to exclude a segment containing
CT repeats. A thymidine kinase gene cassette was inserted
39 of the construct as a negative selection marker. ES cells
were transfected with linearized KO.pNT vector, selected
with G418 plus ganciclovir, and screened by Southern blot
analysis. Of 200 ES cell colonies analyzed, two exhibited a
targeted band at 6.1 kb by HindIII digestion (Fig. 1 B) us-
ing probe B or probe C (Fig. 1 A) in addition to the ex-
pected wild-type band at 4.3 kb. Negative clones including
W34, shown in Fig. 1 B, showed only the wild-type band.
One of the positive clones, W19, displayed a single band
corresponding to the targeted band when the Neo probe
was used, indicating a single integration event in the cells
(Fig. 1 B). As a result of random integration, the Neo probe
hybridized to a band of irrelevant size in W34 (Fig. 1 B). A
homologous recombination event in W19 cells was also
confirmed by EcoRI digestion followed by Southern blot
analyses using probe A or the Neo probe (data not shown).
In all cases, a targeted band of the predicted size was de-
tected. Results from the EcoRI digest using probe A (Fig.
1 C) and PCR analyses using primers P1 and P4 (Fig. 1 A)
suggested that homologous recombination occurred 39 of the
EcoRI site of the targeting vector. Thus, there is no dele-
tion in the 59 flanking region of the PSGL-1 coding region
in W19 cells.
W19 cells were microinjected into blastocysts from
C57BL/6 mice and transferred to recipient female mice,
and chimeric mice were obtained. Breeding of the chimera
with C57BL/6 mice yielded heterozygous animals. Homo-
zygous mutant mice were obtained from subsequent breed-
ing between heterozygotes. The animals were genotyped
by Southern blot analysis as shown in Fig. 1 C. Using
probe A, animals with the mutated allele showed an EcoRI
band at 7.1 kb, whereas those carrying the wild-type allele
yielded a band at 5.3 kb.
Verification of a Null Allele for PSGL-1. Northern blot
analysis of thymus and spleen RNA showed high expres-
sion of PSGL-1 messenger RNA in wild-type mice but did
not show any transcript in PSGL-12/2 mice (Fig. 2), indi-
cating that the targeted mutation created a null allele.
To confirm that PSGL-12/2 mice were deficient in cell
surface expression of PSGL-1, leukocytes from the blood
of wild-type, heterozygous, and homozygous mutant ani-
mals were stained with a rabbit anti–PSGL-1 antibody that
was raised to an NH2-terminal peptide of PSGL-1, and an-
alyzed by flow cytometry. Granulocytes were identified by
light-scatter properties and positive staining with anti–Ly-6G
antibody. All granulocytes from wild-type animals ex-
pressed high levels of PSGL-1. In contrast, granulocytes
from the PSGL-12/2 mice did not show specific staining
(Fig. 3), confirming a null mutation. The mean fluores-
cence intensity of PSGL-1 on granulocytes from heterozy-
gous (1/2) mice was z50% of that observed on wild-type
granulocytes, consistent with the presence of only one
PSGL-1 gene allele in the heterozygotes. Lymphocytes from
the blood of PSGL-12/2 mice did not express PSGL-1, as
assessed by flow cytometry (data not shown).
The absence of PSGL-1 expression in lymphoid organs
was also confirmed by immunohistochemistry. Thymus,
spleen, and lymph node from wild-type mice showed posi-
tive staining on lymphocytes, whereas no specific staining
was observed in PSGL-12/2 mice (Fig. 4). Bone marrow
Figure 2. Northern blot analysis of tissue for
PSGL-1 mRNA. Total RNA isolated from the thy-
mus and spleen of PSGL-1 (2/2)  and PSGL-1
(1/1) mice was subjected to electrophoresis, and
the RNA was transferred to a Duralon-UV™
membrane. The PSGL-1 messenger RNA was de-
tected with a probe representing most of the coding
region. The membrane was stripped and probed
with a cDNA probe for b-actin.
Figure 3. Flow cytometric
analysis of PSGL-1 expression on
peripheral blood neutrophils.
Cells from wild-type (1/1;
top), PSGL-11/2  (middle), and
PSGL-12/2 (bottom) mice were
stained with anti–PSGL-1 anti-
bodies (solid line) or polyclonal
rabbit nonimmune IgG (dotted
line) followed by FITC-labeled
goat anti–rabbit IgG. Fluores-
cence intensity is shown on the
x-axis; cell number is presented
on the y-axis.1774 Leukocyte Rolling and Migration in PSGL-1–deficient Mice
was similarly negative for PSGL-1 antigen, in contrast to
that from wild-type mice.
PSGL-1–deficient Mice Develop Normally. PSGL-12/2 mice
developed normally, and their postnatal growth rate was
comparable with that of wild-type mice. Both sexes were fer-
tile. P-selectin and PSGL-1 were previously shown to be cell
surface components of the sperm and ovum, respectively,
leading to the suggestion that cell adhesion involving P-selec-
tin and PSGL-1 might mediate sperm–ova interaction (69).
Our results indicate that the presence of PSGL-1 on the ova,
if confirmed, is not required for fertilization. Similar results
were obtained for the P-selectin–deficient mouse (6).
Histological analysis of thymus, spleen, and peripheral
and mesenteric lymph nodes, where PSGL-1 expression is
high, showed no abnormalities, indicating that PSGL-1 is not
required for normal lymphoid organ structure. This is in
contrast to the abnormal lymph node architecture that
characterizes L-selectin–deficient mice (11). Examination
of the bone marrow revealed normal erythroid and my-
eloid maturation; no abnormalities in cell morphology were
observed. PSGL-12/2 mice showed no signs of infection
up to 12 mo of age, and specifically lacked the ulcerative
cutaneous infections exhibited by P- and E-selectin dou-
ble-deficient mice (12, 13).
PSGL-1–deficient Mice Have Mild Neutrophilia. Leukocyto-
sis is well known to be associated with an inadequate leuko-
Figure 4. Immunohistochemical
analysis of spleen, thymus, lymph
node, and bone marrow. Tissue
from homozygous null (2/2)
and wild-type (1/1) mice is in-
dicated. Fixed tissue sections were
treated with normal goat serum
followed by rabbit anti–mouse
PSGL-1 antibody. Bound anti–
mouse PSGL-1 antibody was vi-
sualized with biotinylated goat
anti–rabbit antibody reacted with
peroxidase-conjugated streptavi-
din. The samples were developed
with 3,39-diaminobenzidine and
counterstained with methylene
blue.1775 Yang et al.
cyte adhesion and emigration phenotype. Modest elevation
of neutrophil counts is observed in P-selectin–deficient
mice (6) and in C2GlnNAc-deficient mice that exhibit par-
tial deficiency of the selectin ligands (70), whereas a re-
markable granulocytosis is observed in P- and E-selectin
double-deficient mice (12) and fucosyltransferase (Fuc-T)
VII–deficient mice that lack ligand activity for all three se-
lectins (71). Therefore, we examined the peripheral blood
counts of wild-type and PSGL-12/2 mice. The total leuko-
cyte counts were not significantly different between wild-
type and PSGL-12/2 mice, whereas the neutrophil counts
in PSGL-12/2 mice were 2.9-fold higher than those in the
wild-type mice (Table I). The eosinophil counts tended to
be higher in PSGL-12/2 mice (3.5-fold elevation, P 5
0.07). The hemoglobin levels and platelet counts in PSGL-
12/2 mice are essentially identical to those of the matched
wild-type controls. The mild neutrophilia observed in
PSGL-12/2 mice is very similar to the 2.4-fold elevation
reported with P-selectin–deficient mice (6). The elevation
of neutrophil counts in the PSGL-12/2 mice suggests a de-
fect in neutrophil adhesion and migration.
Early Neutrophil Migration during Experimental Peritonitis Is
Impaired in PSGL-1–deficient Mice. Neutrophil migration
in the PSGL-12/2 mice was examined in a thioglycollate-
induced peritonitis model. Chemical peritonitis was in-
duced by intraperitoneal thioglycollate injection in both
PSGL-1–deficient mice and matched wild-type controls.
At 2 h after thioglycollate injection, the number of neutro-
phils migrating into the peritoneal cavity in PSGL-12/2
mice was 4.3-fold lower than wild-type mice (Fig. 5 A,
inset). At the 4-h time point, the difference in neutrophil
recruitment between wild-type and PSGL-12/2 mice was
reduced to 1.9-fold (Fig. 5 A). At 8 h after thioglycollate
injection, the absolute number of neutrophils in the perito-
neal cavity of PSGL-1–deficient mice was only slightly lower
(1.5-fold) than in the matched wild-type controls. These
results demonstrate that the kinetics of neutrophil influx
into the peritoneal cavity in PSGL-12/2 mice are charac-
terized by an early defect after the initiation of the inflam-
matory stimuli. Neutrophil migration approaches normal
levels 8 h after exposure to the inflammatory stimuli. To di-
rectly compare the results obtained with the PSGL-1–defi-
cient mice to those with P-selectin–deficient mice, we re-
examined neutrophil migration in the P-selectin–deficient
mice. We observed a 15.7-fold decrease in neutrophil mi-
gration at 2 h (Fig. 5 B, inset), a 3.9-fold decrease at 4 h,
and a 1.7-fold decrease at 8 h compared with wild-type
matched controls (Fig. 5 B), thus confirming earlier results
(6). Our observation in PSGL-1–deficient mice of an early
Table I. Peripheral Blood Counts
Blood cell types Wild-type PSGL-12/2
Total leukocytes (per ml) 7,060 6 597 7,110 6 506
Neutrophils 580 6 60 1,673 6 121*
Lymphocytes 6,282 6 586 5,106 6 394
Monocytes 139 6 35 190 6 41
Eosinophils 55 6 20 193 6 68
Hemoglobin (g/dl) 15.0 6 0.2 15.4 6 0.2
Platelets (3103/ml) 1,038 6 36 1,021 6 39
Blood was collected from the retroorbital plexus of 10 male mice of each
genotype. Data are presented as mean 6 SEM. *P , 0.001 vs. wild-type.
Figure 5. Neutrophil migra-
tion in thioglycollate-induced
peritonitis. PSGL-1–deficient
mice with matched controls and
P-selectin–deficient mice with
matched controls were studied
in parallel. Absolute neutrophil
counts in the peritoneal exudate
were determined at the indicated
times after induction of experi-
mental peritonitis with thiogly-
collate. An expanded compari-
son at 2 h is presented in the
inset. (A) PSGL-12/2 mice (d,
and [inset] black bars) and
matched wild-type control mice
(s, and [inset] white bars). (B)
P-selectin2/2 mice (j, and [in-
set] black bars) and matched
wild-type control mice (u, and
[inset] white bars). Each data
point represents the average of
the results of 8–10 mice. Data
are presented as mean 6 SEM.
Differences were statistically sig-
nificant (*P  ,  0.001;  #P  5
0.002) compared with respec-
tive wild-type controls.1776 Leukocyte Rolling and Migration in PSGL-1–deficient Mice
defect followed by a significant recovery at later time points
is very similar to that of P-selectin–deficient mice, but dis-
tinct from that observed in P- and E-selectin double-defi-
cient mice in which neutrophil influx remains low at all
time points (12). Although PSGL-12/2 mice and P-selectin2/2
mice showed similar kinetics of neutrophil migration in the
peritonitis model, PSGL-12/2 mice recruited more neutro-
phils at each time point than P-selectin–deficient mice
when each strain was compared with its wild-type control.
It is possible that the difference in the genetic background
of the PSGL-12/2 mice (mixed 129Sv/C57BL/6J/SJL) and
the P-selectin2/2 mice (100% C57BL/6J) may affect the
neutrophil extravasation defect in these strains. Alterna-
tively, these results are consistent with the presence of an
additional P-selectin ligand.
Leukocyte Rolling In Vivo. Leukocyte rolling in the post-
capillary venules of the cremaster muscle was examined by
intravital microscopy in wild-type mice, PSGL-1–deficient
mice, and P-selectin–deficient mice to determine the relative
role of P-selectin and PSGL-1 in leukocyte trafficking in
vivo. This model enables direct examination of granulo-
cytes, which comprise .90% of the adherent leukocytes,
with the blood vessel wall (72). In the first series of experi-
ments, leukocyte rolling was assessed at time points ,30 min
after introduction of the inflammatory stimuli in a model of
mild trauma-induced inflammation. A severe early defect
in leukocyte rolling was observed in the PSGL-1–deficient
animals (Fig. 6). The rolling flux fraction was 1.2% com-
pared with 20.9% in matched wild-type controls (Fig. 6,
and Table II, top) The microvessel and hemodynamic param-
eters in the observed vessels were closely matched across
all of the genotype groups (Table II, top). In agreement
with the results of other investigators (6), P-selectin–defi-
cient animals had a pronounced defect in leukocyte rolling,
with an average leukocyte rolling flux fraction of 0.4%
compared with 18.4% in matched wild-type controls (Fig.
6, and Table II, top). These results emphasize that in mild
trauma-induced inflammation, leukocyte rolling is mark-
edly decreased but not absent in both PSGL-1–deficient
mice and P-selectin–deficient mice within 30 min of intro-
duction of inflammatory stimuli.
To determine the role of PSGL-1 in cytokine-induced
inflammation that is thought to be both P-selectin and
E-selectin mediated, we compared the rolling behavior of
leukocytes in TNF-a–treated cremaster muscles of PSGL-1–
deficient mice and matched wild-type controls. Mice were
treated with TNF-a, then rolling in the venules of the cre-
master muscle was evaluated 2 h later. In contrast to trauma-
induced inflammation, PSGL-1–deficient mice had a sig-
nificant number of rolling leukocytes. A leukocyte rolling
flux fraction of 5.2% (Fig. 7, and Table II, bottom) was ob-
served. The rolling flux fraction of the TNF-a–treated
wild-type mice was 13.9% (Fig. 7, and Table II, bottom).
TNF-a treatment led to reduced blood flow in the micro-
circulation of the cremaster muscle and resulted in lower
wall shear rate values for TNF-a–treated animals than was
observed under conditions of trauma alone (Table II, bot-
tom). Within the TNF-a–treated group, the microvessel and
hemodynamic parameters were similar in both the wild-
type control and PSGL-1 null animals (Table II, bottom).
Comparable results were obtained with the P-selectin–
deficient mice (Fig. 7 D).
To prove that the residual leukocyte rolling in the TNF-a–
treated PSGL-1–deficient mice is mediated by E-selectin,
Figure 6. Leukocyte rolling after mild trauma. Intravital microscopy of
cremaster muscle venules within 30 min of the initiation of surgery re-
vealed the presence of a large number of rolling leukocytes (arrows) asso-
ciated with the vascular wall in wild-type mice (A) and no leukocytes as-
sociated with the vascular wall in PSGL-1–deficient mice (B). Videos
available at http://www.jem.org/cgi/content/full/190/12/1769/F6/
DC1 correspond to A and B. The leukocyte rolling flux fraction, mea-
sured as the number of rolling leukocytes compared with the total leuko-
cytes in flowing blood per unit time, is compared for PSGL-11/1, PSGL-
12/2, P-selectin (P-sel)1/1, and P-selectin2/2 mice in this assay system (C).
Both PSGL-12/2 and P-selectin2/2 mice have low but measurable leuko-
cyte rolling flux fractions.1777 Yang et al.
the blocking anti–E-selectin antibody 9A9 was infused into
the PSGL-1–deficient mouse (8, 73). In TNF-a–treated
PSGL-12/2 mice, the leukocyte rolling flux decreased to
0.6% in the presence of 9A9 (Fig. 7, and Table II, bottom).
Leukocytes visible in the still photograph of the cremaster
venules from a PSGL-1–deficient mouse treated with both
TNF-a and antibody 9A9 (Fig. 7 C) are stationary on the
vessel wall and likely adhered via integrins before the infu-
sion of 9A9. In contrast, antibody 9A9 infused into TNF-a–
treated wild-type mice had a leukocyte rolling flux of
24.9% (Fig. 7 D). This is likely due to the increased average
leukocyte rolling velocity when slow E-selectin–mediated
rolling is substituted by faster P-selectin–mediated rolling.
In sum, these results indicate that PSGL-1 is not required
for E-selectin–mediated leukocyte rolling. The basis for re-
sidual rolling after blocking of E-selectin–mediated leuko-
cyte–vessel wall interaction is uncertain, but is consistent
with interaction of P-selectin with a ligand on leukocytes
other than PSGL-1.
Discussion
The counterreceptors on cell surfaces that bind specifi-
cally to the selectin family of adhesion molecules have been
difficult to identify, although many candidate selectin
ligands have been put forth. As lectins, the selectins bind
predominantly oligosaccharide sequences of sialylated fuco-
sylated lactosamine. These sequences are recognized by the
selectins in vitro, albeit with low affinity (for a review, see
Varki [74]). Many carbohydrates, glycoproteins, or glyco-
lipids bearing these oligosaccharide sequences will bind to
the selectins in vitro when the receptor or ligand is pre-
sented at high density or under static conditions. The issue
in understanding the biology of selectin ligands has been to
prove specific interaction of candidate ligands with selectins
under physiological conditions (47, 75).
Although in vitro studies performed with isolated selec-
tins and potential ligands or by cell adhesions assays have
been invaluable in defining candidates in the inflammatory
pathway, the determination of physiological import of each
of these adhesion molecules requires study in animal mod-
els. The three selectins contribute to leukocyte rolling on
the endothelial cell lining of venules in a cooperative and
sequential manner in the early stages of the inflammatory
process. Genetic disruption of the P-selectin gene in mice
demonstrated that P-selectin is required for neutrophil roll-
ing in postcapillary venules and for neutrophil influx into
inflamed peritoneum at early time points (6, 7). These stud-
ies defined a critical role for P-selectin in early inflamma-
tory events and led to the understanding that P-selectin ini-
tiates leukocyte rolling at sites of inflammation and tissue
injury. Disruption of the L-selectin gene in mice established
that this molecule is also essential for normal leukocyte roll-
ing and emigration into the inflamed peritoneum (7, 11).
L-selectin mediates leukocyte rolling in inflamed venules
sequentially after P-selectin at time points between 40 and
120 min (7). In addition to defects in neutrophil rolling and
migration, the L-selectin–deficient mice had significant de-
fects in lymphocyte homing to peripheral lymphoid tissue
(11, 76). Mice lacking E-selectin initially demonstrated no
defects in the inflammatory response (77). However, detailed
analysis later showed that slow, stable granulocyte rolling
was absent in E-selectin null mice (10) and that E-selectin
was required for firm leukocyte attachment (78). Further
studies using blocking E-selectin antibodies demonstrated
that E-selectin adhesive functions overlap with P-selectin
in the later phases (.2 h) of inflammation (79). The coop-
erative and overlapping function of the selectins is demon-
strated in mice that are doubly deficient in both P-selectin
and E-selectin. Unlike mice deficient in a single selectin,
mice deficient for both P-selectin and E-selectin are char-
acterized by spontaneous skin infections, leukocytosis, and
Table II. Microvessel Parameters
Genotype Mice Vessels Vessel diameter Wall shear rate Rolling flux fraction
mms 21 %
Trauma-induced inflammation
PSGL-11/1 4 23 40.1 6 1.9 1,460 6 158 20.9 6 1.6
PSGL-12/2 7 36 33.2 6 1.2 1,311 6 148 1.2 6 0.3
P-selectin1/1 5 31 37.3 6 1.6 1,259 6 143 18.4 6 1.2
P-selectin2/2 4 24 33.1 6 1.7 1,034 6 110 0.4 6 0.2
TNF-a–induced inflammation
PSGL-11/1 5 25 37.5 6 2.4 905 6 101 13.9 6 1.3
PSGL-12/2 4 27 33.7 6 1.1 857 6 95 5.2 6 0.7
PSGL-12/2 1 9A9 4 24 36.0 6 1.7 767 6 97 0.6 6 0.1
P-selectin1/1 4 36 34.7 6 1.6 805 6 91 12.7 6 1.6
P-selectin2/2 4 28 34.1 6 1.5 767 6 76 5.1 6 0.71778 Leukocyte Rolling and Migration in PSGL-1–deficient Mice
drastic reduction in leukocyte rolling and neutrophil migra-
tion into the inflamed peritoneum at both early and late
time points (12, 13).
Thus, animal studies have demonstrated that P-selectin is
required to initiate early contact of leukocytes with the
vessel wall, and that after this initial step there is significant
cooperativity of function of all three selectins. Using a
PSGL-1–deficient mouse, we have explored the role of this
glycoprotein in selectin-mediated leukocyte adhesion with
the specific goal of determining whether PSGL-1 is the
sole ligand for P-selectin and whether PSGL-1 interaction
with E-selectin is important for the propagation of the nor-
mal inflammatory response.
We have now demonstrated that early neutrophil migration
after chemically induced peritonitis is impaired in PSGL-1–
deficient mice. Previous reports demonstrated that neutro-
phil migration into inflamed peritoneum is impaired in
mice that lack P-selectin or L-selectin but not E-selectin (6,
11, 77). P-selectin–deficient mice and L-selectin–deficient
mice demonstrate depressed neutrophil migration at the early
time points (2–4 h) after chemical insult. In contrast, mice
that lack Fuc-T VII or are deficient in both P-selectin and
E-selectin show a marked reduction in neutrophil migra-
tion at time points up to 8 h (12, 71). Thus, in this assay
deficiency of multiple selectin functions results in a more
severe phenotype. In our chemical peritonitis studies, the
PSGL-1–deficient animals demonstrated a defect in neutro-
phil migration that was marked at 2 h (77% reduction) but
was only minimally abnormal at the later time points. This
phenotype more closely resembled that of P-selectin–defi-
cient mice than the severe migration defect seen in mice
deficient in both P-selectin and E-selectin (12, 13). When
compared with the P-selectin–deficient mice, the PSGL-1–
deficient mice had significantly more neutrophils migrating
into the inflamed peritoneum at parallel time points. These
findings suggest the presence of additional P-selectin ligands
other than PSGL-1, although PSGL-1 nonetheless appears
to be an important and dominant P-selectin ligand.
Our leukocyte rolling experiments have shown that
early trauma-induced leukocyte–endothelial cell interac-
tion is greatly reduced, whereas cytokine-induced leuko-
cyte rolling is only modestly impacted in the PSGL-1–defi-
Figure 7. Leukocyte rolling after TNF-a stimulation. Intravital microscopy
of cremaster muscle venules 2 h after injection of TNF-a into the scrotal sac re-
vealed the presence of rolling leukocytes (arrows) associated with the vascular
wall in wild-type mice (A) and in PSGL-1–deficient mice (B). Infusion of the
blocking E-selectin antibody 9A9 into PSGL-1–deficient mice greatly reduced
the number of rolling leukocytes; leukocytes visible in C are stationary. Videos
available at http://www.jem.org/cgi/content/full/190/12/1769/F7/DC1 cor-
respond to A and B, and to two time points in C, showing leukocyte rolling be-
fore infusion of anti–E-selectin antibody, and leukocyte rolling during and after
infusion of anti–E-selectin antibody, respectively. The leukocyte rolling flux
fraction, measured as the number of rolling leukocytes compared with the
total leukocytes in flowing blood per unit time, is compared for PSGL-11/1
mice, PSGL-12/2 mice, PSGL-12/2 mice treated with anti–E-selectin antibody
9A9, PSGL-11/1 mice treated with anti–E-selectin antibody 9A9, P-selectin
(P-sel)1/1 mice, and P-selectin2/2 mice in this assay system (D).1779 Yang et al.
cient mice. Trauma-induced neutrophil rolling in the
postcapillary venules of P-selectin–deficient and L-selectin–
deficient mice is reduced initially but approaches normal
levels as inflammation progresses (6, 7, 11). In contrast,
neutrophil rolling is virtually absent in trauma- and TNF-a–
induced inflammation in mice deficient in both P-selectin
and E-selectin (12, 13). In our current work, we have es-
tablished that PSGL-1 is required for the early, P-selectin–
mediated phases of leukocyte rolling at times ,30 min after
the inflammatory stimulus. Similar to the P-selectin–deficient
mice, neutrophil rolling in PSGL-1–deficient mice is reduced
by z95% compared with wild-type mice. Based on this
observation, PSGL-1 appears to be the dominant P-selectin
ligand early in trauma-induced inflammatory events.
TNF-a is a cytokine that induces E-selectin biosynthesis
in endothelial cells and promotes leukocyte rolling in part
mediated by E-selectin. Mice deficient in both P-selectin
and E-selectin have profound leukocyte rolling defects in
TNF-a–treated venules (12, 13). In our studies, the PSGL-1–
deficient mice demonstrated a significant amount of leuko-
cyte rolling (5.2% flux) after 2 h of pretreatment with
TNF-a. The leukocyte rolling flux for the TNF-a–treated
PSGL-1–deficient mice (5.2%) was identical to that of
TNF-a–treated P-selectin–deficient mice (5.1%) and is signif-
icantly higher than the leukocyte rolling flux reported in
TNF-a–primed mice deficient in both P-selectin and E-selec-
tin (12, 13). This finding suggests that PSGL-1 functions
mainly as a P-selectin ligand in this system; the preserved
function of E-selectin and L-selectin with their comple-
mentary counterreceptors supports a TNF-a–induced roll-
ing flux in the absence of P-selectin or PSGL-1. Further-
more, the presence of a measurable leukocyte rolling flux
in the PSGL-1–deficient mouse raises questions of the im-
portance of leukocyte–leukocyte rolling interactions medi-
ated by L-selectin and PSGL-1.
Leukocytosis, the hallmark of a major defect in host de-
fense, is often associated with recurrent infection or chronic
ulceration as a manifestation of blockade of leukocyte ac-
tivity. Mice deficient in both P-selectin and E-selectin (12,
13) and mice deficient in the fucosyltransferase required for
synthesis of the selectin ligands (71) exhibit leukocytosis.
However, our PSGL-1–deficient mice exhibited only a
mild elevation of neutrophils. Since genetic deficiency of
P-selectin, E-selectin, L-selectin, or, from these studies,
PSGL-1, is not associated with significant leukocytosis, it
would appear that the presence of 5% of normal leukocyte
rolling and delayed neutrophil migration comprises an ade-
quate host defense. Thus, no single deficiency of a selectin or
selectin ligand causes a phenotype of leukocytosis, chronic
infection, and early demise. This observation speaks to the
importance of redundancy in these host defense systems. It
is also consistent with our observation that PSGL-1 is the
dominant ligand for P-selectin, but not required for the func-
tion of E-selectin within the context of leukocyte rolling.
These experiments using PSGL-1–deficient mice have
established that PSGL-1 is a critical P-selectin ligand early
in inflammation. Comparison of the phenotype of the
PSGL-1–deficient mouse and the mouse deficient in both
P-selectin and E-selectin (12, 13) provides evidence that
PSGL-1 is not a required neutrophil ligand for E-selectin–
mediated neutrophil rolling. In contrast to the mice deficient
in both P-selectin and E-selectin, the PSGL-1–deficient
mice have no leukocytosis, no susceptibility to spontaneous
infection, and have detectable leukocyte rolling and adequate
neutrophil migration into the inflamed peritoneum after in-
flammatory stimuli. If PSGL-1 were the sole ligand for
both P-selectin and E-selectin, the PSGL-1–deficient mice
and the mice deficient in both P-selectin and E-selectin
would have the same phenotype. These data provide strong
evidence for the existence of additional physiological
ligands for E-selectin, perhaps ESL-1 (31), and do not sup-
port a requirement for PSGL-1 in E-selectin–mediated
neutrophil rolling. The relative importance of PSGL-1–
E-selectin interaction during T cell homing (40, 80) is un-
resolved, but further studies using PSGL-1–deficient mice
will address this important question.
We are grateful to Dr. Harold Dvorak for his interpretation of the mouse tissue histology, Dr. Lia Palomba
for preparing the antibodies to mouse PSGL-1, Dr. Andrea Bottaro for technical advice in generating the
knockout construct, Dr. Barry Wolitzky for supplying antibodies to E-selectin, Dr. Pamela Stanley for the
ES cells, and Dr. Klaus Ley for teaching us his in vivo leukocyte rolling assay.
This work was supported by grant HL51926 from the National Institutes of Health.
Address correspondence to Bruce Furie, Beth Israel Deaconess Cancer Center, Kirstein 153, Beth Israel
Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215. Phone: 617-667-0620; Fax: 617-975-
8030; E-mail: bfurie@caregroup.harvard.edu
J. Yang’s present address is Department of Medicine, University of Pennsylvania School of Medicine, Phila-
delphia, PA 19104.
Submitted: 10 June 1999 Revised: 24 August 1999 Accepted: 21 September 1999
References
1. Springer, T.A. 1994. Traffic signals for lymphocyte recircula-
tion and leukocyte emigration: the multistep paradigm. Cell.
76:301–314.
2. Tedder, T.F., D.A. Steeber, A. Chen, and P. Engel. 1995.1780 Leukocyte Rolling and Migration in PSGL-1–deficient Mice
The selectins: vascular adhesion molecules. FASEB J. 9: 866–
873.
3. McEver, R.P., K.L. Moore, and R.D. Cummings. 1995.
Leukocyte trafficking mediated by selectin-carbohydrate in-
teractions. J. Biol. Chem. 270:11025–11028.
4. Stenberg, P.E., R.P. McEver, M.A. Shuman, Y.V. Jacques,
and D.F. Bainton. 1985. A platelet alpha-granule membrane
protein GMP140 is expressed on the plasma membrane after
activation. J. Cell Biol. 101:880–886.
5. Berman, C.L., E. Yeo, J.D. Wencel-Drake, B.C. Furie,
M.H. Ginsberg, and B. Furie. 1986. A platelet alpha granule
membrane protein that is incorporated into the plasma mem-
brane during activation. Characterization and subcellular lo-
calization of PADGEM protein. J. Clin. Invest. 78:130–137.
6. Mayadas, T.N., R.C. Johnson, H. Rayburn, R.O. Hynes,
and D.D. Wagner. 1993. Leukocyte rolling and extravasation
are severely compromised in P-selectin-deficient mice. Cell.
74:541–554.
7. Ley, K., D.C. Bullard, M.L. Arbones, R. Bosse, D. Vestwe-
ber, T.F. Tedder, and A.L. Beaudet. 1995. Sequential contri-
bution of L- and P-selectin to leukocyte rolling in vivo. J.
Exp. Med. 181:669–675.
8. Kunkel, E.J., U. Jung, D.C. Bullard, K.E. Norman, B.A.
Wolitzky, D. Vestweber, A.L. Beaudet, and K. Ley. 1996.
Absence of trauma-induced leukocyte rolling in mice defi-
cient in both P-selectin and intercellular adhesion molecule
1. J. Exp. Med. 183:57–65.
9. Bevilacqua, M.P., S. Stengalin, M.A. Gimbrone, Jr., and B.
Seed. 1989. Endothelial leukocyte adhesion molecule 1: an
inducible receptor for neutrophils related to complement
regulatory proteins and lectins. Science. 243:1160–1165.
10. Kunkel, E.J., and K. Ley. 1996. Distinct phenotype of
E-selectin-deficient mice. E-selectin is required for slow leu-
kocyte rolling in vivo. Circ. Res. 79:1196–1204.
11. Arbones, M.L., D.C. Ord, K. Ley, H. Ratech, C.C. May-
nard, G. Otten, D.J. Capon, and T.F. Tedder. 1994. Lym-
phocyte homing and leukocyte rolling and migration are im-
paired in L-selectin-deficient mice. Immunity. 1:247–260.
12. Frenette, P.S., T.N. Mayadas, H. Rayburn, R.O. Hynes, and
D.D. Wagner. 1996. Susceptibility to infection and altered
hematopoiesis in mice deficient in both P- and E-selectins.
Cell. 84:563–574.
13. Bullard, D.C., E.J. Kunkel, H. Kubo, M.J. Hicks, I. Lorenzo,
N.A. Doyle, C.M. Doerschuk, K. Ley, and A.L. Beaudet.
1996. Infectious susceptibility and severe deficiency of leuko-
cyte rolling and recruitment in E-selectin and P-selectin dou-
ble mutant mice. J. Exp. Med. 183:2329–2336.
14. Larsen, E., T. Palabrica, S. Sajer, G.E. Gilbert, D.D. Wagner,
B.C. Furie, and B. Furie. 1990. PADGEM-dependent adhe-
sion of platelets to monocytes and neutrophils is mediated by
a lineage-specific carbohydrate, LNF III (CD15). Cell. 63:
467–474.
15. Polley, M.J., M.L. Phillips, E. Wayner, E. Nudelman, A.K.
Singhal, S. Hakomori, and J.C. Paulson. 1991. CD62 and
endothelial cell-leukocyte adhesion molecule 1 ELAM-1 rec-
ognize the same carbohydrate ligand, sialyl-Lewis x. Proc.
Natl. Acad. Sci. USA. 88:6224–6228.
16. Foxall, C., S.R. Watson, D. Dowbenko, C. Fennie, L.A.
Lasky, M. Kiso, A. Hasegawa, D. Asa, and B.K. Brandley.
1992. The three members of the selectin receptor family rec-
ognize a common carbohydrate epitope, the sialyl Lewis(x)
oligosaccharide. J. Cell Biol. 117:895–902.
17. Picker, L.J., R.A. Warnock, A.R. Burns, C.M. Doerschuk,
E.L. Berg, and E.C. Butcher. 1991. The neutrophil selectin
LECAM-1 presents carbohydrate ligands to the vascular se-
lectins ELAM-1 and GMP-140. Cell. 66:921–933.
18. Lasky, L.A., M.S. Singer, D. Dowbenko, Y. Imai, W.J. Hen-
zel, C. Grimley, C. Fennie, N. Gillett, S.R. Watson, and
S.D. Rosen. 1992. An endothelial ligand for L-selectin is a
novel mucin-like molecule. Cell. 69:927–938.
19. Baumheuter, S., M.S. Singer, W. Henzel, S. Hemmerich, M.
Renz, S.D. Rosen, and L.A. Lasky. 1993. Binding of L-selec-
tin to the vascular sialomucin CD34. Science. 262:436–438.
20. Baumheuter, S., N. Dybdal, C. Kyle, and L.A. Lasky. 1994.
Global vascular expression of murine CD34, a sialomucin-
like endothelial ligand for L-selectin. Blood. 84:2554–2565.
21. Hemmerich, S., E.C. Butcher, and S.D. Rosen. 1994. Sulfa-
tion-dependent recognition of high endothelial venule
(HEV)-ligands by L-selectin and MECA 79, and adhesion-
blocking monoclonal antibody. J. Exp. Med. 180:2219–2226.
22. Berg, E.L., L.M. McEvoy, C. Berlin, R.F. Bargatze, and
E.C. Butcher. 1993. L-selectin-mediated lymphocyte rolling
on MAdCAM-1. Nature. 366:695–698.
23. Guyer, D.A., K.L. Moore, E.B. Lynam, C.M. Schammel, S.
Rogelj, R.P. McEver, and L.A. Sklar. 1996. P-selectin gly-
coprotein ligand-1 (PSGL-1) is a ligand for L-selectin in neu-
trophil aggregation. Blood. 88:2415–2421.
24. Spertini, O., A.S. Cordey, N. Monai, L. Giuffre, and M.
Schapira. 1996. P-selectin glycoprotein ligand 1 is a ligand
for L-selectin on neutrophils, monocytes, and CD341 he-
matopoietic progenitor cells. J. Cell Biol. 135:523–531.
25. Tu, L., A. Chen, M.D. Delahunty, K.L. Moore, S.R. Wat-
son, R.P. McEver, and T.F. Tedder. 1996. L-selectin binds
to P-selectin glycoprotein ligand-1 on leukocytes: interac-
tions between the lectin, epidermal growth factor, and con-
sensus repeat domains of the selectins determine ligand bind-
ing specificity. J. Immunol. 157:3995–4004.
26. Alon, R., R.C. Fuhlbrigge, E.B. Finger, and T.A. Springer.
1996. Interactions through L-selectin between leukocytes
and adherent leukocytes nucleate rolling adhesions on selec-
tins and VCAM-1 in shear flow. J. Cell Biol. 135:849–865.
27. Bargatze, R.F., S. Kurk, E.C. Butcher, and M.A. Jutila. 1994.
Neutrophils roll on adherent neutrophils bound to cytokine-
induced endothelial cells via L-selectin on the rolling cells. J.
Exp. Med. 180:1785–1792.
28. Jutila, M.A., and S. Kurk. 1996. Analysis of bovine gamma
delta T cell interactions with E-, P-, and L-selectin. Charac-
terization of lymphocyte on lymphocyte rolling and the ef-
fects of O-glycoprotease. J. Immunol. 156:289–296.
29. Walcheck, B., K.L. Moore, R.P. McEver, and T.K. Kishi-
moto. 1996. Neutrophil–neutrophil interactions under hydro-
dynamic shear stress involve L-selectin and PSGL-1. A
mechanism that amplifies initial leukocyte accumulation of
P-selectin in vitro. J. Clin. Invest. 98:1081–1087.
30. Patel, K.D., and R.P. McEver. 1997. Comparison of tether-
ing and rolling of eosinophils and neutrophils through selec-
tins and P-selectin glycoprotein ligand-1. J. Immunol. 159:
4555–4565.
31. Levinovitz, A., J. Muhlhoff, S. Isenmann, and D. Vestweber.
1993. Identification of a glycoprotein ligand for E-selectin on
mouse myeloid cells. J. Cell Biol. 121:449–459.
32. Jones, W.M., G.M. Watts, M.K. Robinson, D. Vestweber,
and M.A. Jutila. 1997. Comparison of E-selectin-binding
glycoprotein ligands on human lymphocytes, neutrophils,
and bovine gamma delta T cells. J. Immunol. 159:3574–3583.
33. Zollner, O., M.C. Lenter, J.E. Blanks, E. Borges, M. Steeg-1781 Yang et al.
maier, H.G. Zerwes, and D. Vestweber. 1997. L-selectin
from human, but not from mouse neutrophils binds directly
to E-selectin. J. Cell Biol. 136:707–716.
34. Sako, D., X.J. Chang, K.M. Barone, G. Vachino, H.M.
White, G. Shaw, G.M. Veldman, K.M. Bean, T.J. Ahern, B.
Furie, et al. 1993. Expression cloning of a functional glyco-
protein ligand for P-selectin. Cell. 75:1179–1186.
35. Asa, D., L. Raycroft, L. Ma, P.A. Aeed, P.S. Kaytes, A.P. El-
hammer, and J.G. Geng. 1995. The P-selectin glycoprotein
ligand functions as a common human leukocyte ligand for P-
and E-selectins. J. Biol. Chem. 270:11662–11670.
36. Goetz, D.J., D.M. Greif, H. Ding, R.T. Camphausen, S.
Howes, K.M. Comess, K.R. Snapp, G.S. Kansas, and F.W.
Luscinskas. 1997. Isolated P-selectin glycoprotein ligand-1
dynamic adhesion to P- and E-selectin. J. Cell Biol. 137:
509–519.
37. Li, F., P.P. Wilkins, S. Crawley, J. Weinstein, R.D. Cum-
mings, and R.P. McEver. 1996. Post-translational modifica-
tions of recombinant P-selectin glycoprotein ligand-1 required
for binding to P- and E-selectin. J. Biol. Chem. 271:3255–3264.
38. Moore, K.L., S.F. Eaton, D.E. Lyons, H.S. Lichenstein,
R.D. Cummings, and R.P. McEver. 1994. The P-selectin
glycoprotein ligand from human neutrophils displays sialy-
lated, fucosylated, O-linked poly-N-acetyllactosamine.  J.
Biol. Chem. 269:23318–23327.
39. Patel, K.D., K.L. Moore, M.U. Nollert, and R.P. McEver.
1995. Neutrophils use both shared and distinct mechanisms
to adhere to selectins under static and flow conditions. J.
Clin. Invest. 96:1887–1896.
40. Borges, E., G. Pendl, R. Eytner, M. Steegmaier, O. Zollner,
and D. Vestweber. 1997. The binding of T cell-expressed
P-selectin glycoprotein ligand-1 to E- and P-selectin is dif-
ferentially regulated. J. Biol. Chem. 272:28786–28792.
41. Sammar, M., S. Aigner, M. Hubbe, V. Schirrmacher, M.
Schachner, D. Vestweber, and P. Altevogt. 1994. Heat-stable
antigen CD24 as ligand for mouse P-selectin. Int. Immunol.
6:1027–1036.
42. Aigner, S., C.L. Ramos, A. Hafezi-Moghadam, M.B. Law-
rence, J. Friederichs, P. Altevogt, and K. Ley. 1998. CD24
mediates rolling of breast carcinoma cells on P-selectin.
FASEB J. 12:1241–1251.
43. Aigner, S., Z.M. Sthoeger, M. Fogel, E. Weber, J. Zarn, M.
Ruppert, Y. Zeller, D. Vestweber, R. Stahel, M. Sammar,
and P. Altevogt. 1997. CD24, a mucin-type glycoprotein, is
a ligand for P-selectin on human tumor cells. Blood. 89:
3385–3395.
44. Aruffo, A., W. Kolanus, G. Walz, P. Fredman, and B. Seed.
1991. CD62/P-selection recognition of myeloid and tumor
cell sulfatides. Cell. 67:35–44.
45. Diacovo, T.G., K.D. Puri, R.A. Warnock, T.A. Springer,
and U.H. von Andrian. 1996. Platelet-mediated lymphocyte
delivery to high endothelial venules. Science. 273:252–255.
46. Moore, K.L., K.D. Patel, R.E. Bruehl, F. Li, D.A. Johnson,
H.S. Lichenstein, R.D. Cummings, D.F. Bainton, and R.P.
McEver. 1995. P-selectin glycoprotein ligand-1 mediates
rolling of human neutrophils on P-selectin. J. Cell Biol. 128:
661–671.
47. Varki, A. 1997. Selectin ligands: will the real ones please
stand up? J. Clin. Invest. 99:158–162.
48. Norman, K.E., K.L. Moore, R.P. McEver, and K. Ley.
1995. Leukocyte rolling in vivo is mediated by P-selectin
glycoprotein ligand-1. Blood. 86:4417–4421.
49. Borges, E., R. Eytner, T. Moll, M. Steegmaier, M.A. Camp-
bell, K. Ley, H. Mossmann, and D. Vestweber. 1997. The
P-selectin glycoprotein ligand-1 is important for recruitment
of neutrophils into inflamed mouse peritoneum. Blood. 90:
1934–1942.
50. Takada, M., K.C. Nadeau, G.D. Shaw, and N.L. Tilney.
1997. Early cellular and molecular changes in ischemia/re-
perfusion injury: inhibition by a selectin antagonist, P-selectin
glycoprotein ligand-1. Transplant. Proc. 29:1324–1325.
51. Laszik, Z., P.J. Jansen, R.D. Cummings, T.F. Tedder, R.P.
McEver, and K.L. Moore. 1996. P-selectin glycoprotein
ligand-1 is broadly expressed in cells of myeloid, lymphoid,
and dendritic lineage and in some nonhematopoietic cells.
Blood. 88:3010–3021.
52. Vachino, G., X.J. Chang, G.M. Veldman, R. Kumar, D.
Sako, L.A. Fouser, M.C. Berndt, and D.A. Cumming. 1995.
P-selectin glycoprotein ligand-1 is the major counter-recep-
tor for P-selectin on stimulated T cells and is widely distrib-
uted in non-functional form on many lymphocytic cells. J.
Biol. Chem. 270:21966–21974.
53. Fujimoto, T.T., M. Noda, T. Takafuta, T. Shimomura, K.
Fujimura, and A. Kuramoto. 1996. Expression and functional
characterization of the P-selectin glycoprotein ligand-1 in
various cells. Int. J. Hematol. 64:231–239.
54. Diacovo, T.G., S.J. Roth, C.T. Morita, J.P. Rosat, M.B.
Brenner, and T.A. Springer. 1996. Interactions of human
a/b and g/d T lymphocyte subsets in shear flow with E-selec-
tin and P-selectin. J. Exp. Med. 183:1193–1203.
55. Yang, J., J. Galipeau, C.A. Kozak, B.C. Furie, and B. Furie.
1996. Mouse P-selectin glycoprotein ligand-1: molecular
cloning, chromosomal localization, and expression of a func-
tional P-selectin receptor. Blood. 87:4176–4186.
56. Snapp, K.R., R. Craig, M. Herron, R.D. Nelson, L.M.
Stoolman, and G.S. Kansas. 1998. Dimerization of P-selectin
glycoprotein ligand-1 (PSGL-1) required for optimal recog-
nition of P-selectin. J. Cell Biol. 142:263–270.
57. Croce, K., S.J. Freedman, B.C. Furie, and B. Furie. 1998. In-
teraction between soluble P-selectin and soluble P-selectin
glycoprotein ligand 1: equilibrium binding analysis. Biochem-
istry. 37:16472–16480.
58. Sako, D., K.M. Comess, K.M. Barone, R.T. Camphausen,
D.A. Cumming, and G.D. Shaw. 1995. A sulfated peptide
segment at the amino terminus of PSGL-1 is critical for
P-selectin binding. Cell. 83:323–331.
59. Pouyani, T., and B. Seed. 1995. PSGL-1 recognition of
P-selectin is controlled by a tyrosine sulfation consensus at
the PSGL-1 amino terminus. Cell. 83:333–343.
60. Wilkins, P.P., K.L. Moore, R.P. McEver, and R.D. Cum-
mings. 1995. Tyrosine sulfation of P-selectin glycoprotein
ligand-1 is required for high affinity binding to P-selectin. J.
Biol. Chem. 270:22677–22680.
61. Symon, F.A., M.B. Lawrence, M.L. Williamson, G.M.
Walsh, S.R. Watson, and A.J. Wardlaw. 1996. Functional
and structural characterization of the eosinophil P-selectin
ligand. J. Immunol. 157:1711–1719.
62. Veldman, G.M., K.M. Bean, D.A. Cumming, R.L. Eddy,
S.N. Sait, and T.B. Shows. 1995. Genomic organization and
chromosomal localization of the gene encoding human P-selec-
tin glycoprotein ligand. J. Biol. Chem. 270:16470–16475.
63. Li, F., H.P. Erickson, J.A. James, K.L. Moore, R.D. Cum-
mings, and R.P. McEver. 1996. Visualization of P-selectin
glycoprotein ligand-1 as a highly extended molecule and
mapping of protein epitopes for monoclonal antibodies. J.
Biol. Chem. 271:6342–6348.1782 Leukocyte Rolling and Migration in PSGL-1–deficient Mice
64. Liu, W., V. Ramachandran, J. Kang, T.K. Kishimoto, R.D.
Cummings, and R.P. McEver. 1998. Identification of N-ter-
minal residues on P-selectin glycoprotein ligand-1 required
for binding to P-selectin. J. Biol. Chem. 273:7078–7087.
65. Ioffe, E., Y. Liu, M. Bhaumik, F. Poirier, S.M. Factor, and P.
Stanley. 1995. WW6: an embryonic stem cell line with an
inert genetic marker that can be traced in chimeras. Proc.
Natl. Acad. Sci. USA. 92:7357–7361.
66. Lipowsky, H.H., and B.W. Zweifach. 1978. Application of
the “two-slit” photometric technique to the measurement of
microvascular volumetric flow rates. Microvasc. Res. 15:93–101.
67. Krayev, A.S., T.V. Markusheva, D.A. Kramerov, A.P.
Ryskov, K.G. Skyabin, A.A. Bayev, and G.P. Georgiev. 1982.
Ubiquitous transposon-like repeats B1 and B2 of the mouse
genome: B2 sequencing. Nucleic Acids Res. 10:7461–7475.
68. La Volpe, A., A. Simeone, M. D’Esposito, L. Scotto, V. Fi-
danza, A. de Falco, and E. Boncinelli. 1985. Molecular anal-
ysis of the heterogeneity region of the human ribosomal
spacer.  J. Mol. Biol. 183:213–223.
69. Geng, J.G., T.J. Raub, C.A. Baker, G.A. Sawada, L. Ma, and
A.P. Elhammer. 1997. Expression of a P-selectin ligand in
zona pellucida of porcine oocytes and P-selectin on acroso-
mal membrane of porcine sperm cells. Potential implications
for their involvement in sperm–egg interactions. J. Cell Biol.
137:743–754.
70. Ellies, L.G., S. Tsuboi, B. Petryniak, J.B. Lowe, M. Fukuda,
and J.D. Marth. 1998. Core 2 oligosaccharide biosynthesis
distinguishes between selectin ligands essential for leukocyte
homing and inflammation. Immunity. 9:881–890.
71. Maly, P., A. Thall, B. Petryniak, C.E. Rogers, P.L. Smith,
R.M. Marks, R.J. Kelly, K.M. Gersten, G. Cheng, T.L.
Saunders, et al. 1996. The alpha1,3fucosyltransferase Fuc-
TVII controls leukocyte trafficking through an essential role
in L-, E-, and P-selectin ligand biosynthesis. Cell. 86:643–653.
72. Jung, U., D.C. Bullard, T.F. Tedder, and K. Ley. 1996. Ve-
locity differences between L- and P-selectin-dependent neu-
trophil rolling in venules of mouse cremaster muscle in vivo.
Am. J. Physiol. 271:H2740–H2747.
73. Norton, C.R., J.M. Rumberger, D.K. Burns, and B.A.
Wolitzky. 1993. Characterization of murine E-selectin ex-
pression in vitro using novel anti-mouse E-selectin mono-
clonal antibodies. Biochem. Biophys. Res. Commun.195:250–258.
74. Varki, A. 1994. Selectin ligands. Proc. Natl. Acad. Sci. USA.
91:7390–7397.
75. Vestweber, D. 1996. Ligand-specificity of the selectins. J.
Cell. Biochem. 61:585–591.
76. Steeber, D.A., N.E. Green, S. Sato, and T.F. Tedder. 1996.
Lymphocyte migration in L-selectin-deficient mice. Altered
subset migration and aging of the immune system. J. Immu-
nol. 157:1096–1106.
77. Labow, M.A., C.R. Norton, J.M. Rumberger, G.K. Lom-
bard, D.J. Shuster, J. Hubbard, R. Bertko, P.A. Knaack,
R.W. Terry, M.L. Harbison, et al. 1994. Characterization of
E-selectin-deficient mice: demonstration of overlapping
function of the endothelial selectins. Immunity. 1:709–720.
78. Ley, K., M. Allietta, D.C. Bullard, and S. Morgan. 1998. Im-
portance of E-selectin for firm leukocyte adhesion in vivo.
Circ. Res. 83:287–294.
79. Ramos, C.L., E.J. Kunkel, M.B. Lawrence, U. Jung, D.
Vestweber, R. Bosse, K.W. McIntyre, K.M. Gillooly, C.R.
Norton, B.A. Wolitzky, and K. Ley. 1997. Differential effect
of E-selectin antibodies on neutrophil rolling and recruit-
ment to inflammatory sites. Blood. 89:3009–3018.
80. Fuhlbrigge, R.C., J.D. Kieffer, D. Armerding, and T.S. Kup-
per. 1997. Cutaneous lymphocyte antigen is a specialized
form of PSGL-1 expressed on skin-homing T cells. Nature.
389:978–981.